在转移性细胞癌中,lncRNA和转录基因组交叉点与针对性治疗的响应有关
Tereza Tesarova1,2, Kamila Koucka1, Radka Vaclavikova1,2
1Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic.
Oncology letters
|August 10, 2023
概括
长非编码RNAs (lncRNAs) 是癌症进展的关键,可以预测治疗反应. 这项研究在转移性细胞癌患者中确定了与sunitinib有效性相关的特定lncRNAs.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 长非编码RNAs (lncRNAs) 在癌症的发展和进展中起着至关重要的作用.
- lncRNAs是癌症诊断和预后的潜在分子生物标志物.
- 转移性细胞癌 (mRCC) 的治疗反应在患者之间可能有很大的差异.
研究的目的:
- 为了识别与对受体氨酸激酶抑制剂sunitinib反应相关的lncRNAs.
- 分析mRCC患者的转录组形状和临床特征.
- 发现mRCC的新型预测和预后生物标志物.
主要方法:
- 量化PCR用于评估38名mRCC患者瘤和非恶性组织中84种癌症相关lncRNA的基因表达.
- 对20名患者的小组进行了RNA测序,以评估编码转录基因组.
- 确定了mRNA-lncRNA交叉点,以了解调节网络.
主要成果:
- 与相邻的非恶性组织相比,瘤组织中有37个lncRNAs的调节下降,13个的调节上升.
- 10个lncRNAs被上调和4被下调在良好的响应者对较差的响应者sunitinib.
- 高度表达HNF1A-AS1和IPW lncRNAs与长期无进展生存相关,而高度的TUSC7表达表明反应和生存不佳.
- 失调的MEG3和SNHG16 lncRNAs与蛋白质编码基因表达有显著的关联.
- 在良好的反应者中,CLIP4基因被显著上调.
结论:
- 特定的lncRNAs,包括HNF1A-AS1,IPW和TUSC7,显示出在mRCC中作为sunitinib反应的预测生物标志物的潜力.
- 像MEG3和SNHG16这样的lncRNA与mRCC相关的分子通路有关.
- 这些发现突出了有希望的lncRNA候选人,以改善mRCC.患者分层和治疗策略.
关键词:
抑制剂抑制剂的使用长非编码RNA是什么意思转移性转移性 转移性预后 预后 预后癌 癌 癌 癌 癌响应 响应 响应 响应苏尼提尼布 (sunitinib) 的使用方法治疗疗法治疗疗法治疗疗法转录组 (transcriptome) 是一个转录组.铁氨酸激酶酶的使用方法更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.9K
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
33.6K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K